Nicole Seguin-Basset
Paris, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 119 publications
Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma.
Journal: The New England journal of medicine
Published: June 02, 2025
Genomic and clinical characterization of anogenital basal cell carcinoma: A retrospective and prospective cohort study.
Journal: Journal of the American Academy of Dermatology
Published: February 12, 2025
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2024.
Journal: European journal of cancer (Oxford, England : 1990)
Published: November 22, 2024
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024.
Journal: European journal of cancer (Oxford, England : 1990)
Published: November 21, 2024
Effectiveness, safety and reasons for discontinuation of sonidegib for patients with locally advanced basal cell carcinoma: A real-word evidence analysis from the French national registry CARADERM.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: May 14, 2024
A European Consensus on the Consistent Use of the Term "Keratinocyte Cancer".
Journal: Acta dermato-venereologica
Published: April 17, 2024
High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma.
High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma.
Journal: Journal for immunotherapy of cancer
Published: February 14, 2024
Operational classification of cutaneous squamous cell carcinomas based on unsupervised clustering of real cases by experts.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: January 22, 2024
Re-evaluation of the concept of basaloid follicular hamartoma associated with naevoid basal cell carcinoma syndrome: a morphological, immunohistochemical and molecular study.
Journal: Pathology
Published: January 16, 2024
A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6.
Journal: Journal of the American Academy of Dermatology
Published: January 05, 2024
Genomic profiling of a skin adnexal carcinomas cohort using a comprehensive high-throughput sequencing approach.
Journal: The British journal of dermatology
Published: December 13, 2023
Response to "Hedgehog pathway inhibitor real-world treatment patterns in patients with basal cell carcinoma: a claims-based analysis".
Journal: Future oncology (London, England)
Published: November 15, 2023
Last Updated: 09/26/2026